Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients w...

Full description

Bibliographic Details
Main Authors: Yan Gao, Yuan Li, Chunyu Zhang, Jinsong Han, Huamao Liang, Kun Zhang, Hongyan Guo
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Journal of Ovarian Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13048-019-0562-9
id doaj-115a5ae16e13471d9858e595eb826de8
record_format Article
spelling doaj-115a5ae16e13471d9858e595eb826de82020-11-25T02:49:29ZengBMCJournal of Ovarian Research1757-22152019-09-011211810.1186/s13048-019-0562-9Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective studyYan Gao0Yuan Li1Chunyu Zhang2Jinsong Han3Huamao Liang4Kun Zhang5Hongyan Guo6Department of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalAbstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients who benefited from NACT were further evaluated. Methods We retrospectively analyzed 220 patients who underwent NACT followed by IDS or PDS from January 2002 to December 2016. Differences in clinicopathological features, chemoresistance and prognosis were analyzed. Results The incidence rate for optimal cytoreduction and chemoresistance in the NACT group was relatively higher than PDS group. No differences were observed in progression free survival or overall survival. Patients without macroscopic RD in NACT group (NACT-R0) had a similar prognosis compared to those in PDS group who had RD<1 cm, and a relatively better prognosis compared to the PDS group that had RD ≥ 1 cm. The survival curve showed that patients in NACT-R0 group that were chemosensitive seemed to have a better prognosis compared to patients in PDS group that had RD. Conclusion Patients without RD after PDS had the best prognosis, whereas patients with RD after NACT followed by IDS had the worst. However, even if patients achieved no RD, their prognosis varied depending on chemosensitivity. Survival was better in patients who were chemosensitive compared to thosewho underwent PDS but had RD. Hence evaluating the chemosensitivity and feasibility of complete cytoreduction in advance is crucial.http://link.springer.com/article/10.1186/s13048-019-0562-9Advanced ovarian epithelial CancerNeoadjuvant chemotherapyPrimary Debulking surgeryChemoresistancePrognosis
collection DOAJ
language English
format Article
sources DOAJ
author Yan Gao
Yuan Li
Chunyu Zhang
Jinsong Han
Huamao Liang
Kun Zhang
Hongyan Guo
spellingShingle Yan Gao
Yuan Li
Chunyu Zhang
Jinsong Han
Huamao Liang
Kun Zhang
Hongyan Guo
Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
Journal of Ovarian Research
Advanced ovarian epithelial Cancer
Neoadjuvant chemotherapy
Primary Debulking surgery
Chemoresistance
Prognosis
author_facet Yan Gao
Yuan Li
Chunyu Zhang
Jinsong Han
Huamao Liang
Kun Zhang
Hongyan Guo
author_sort Yan Gao
title Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
title_short Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
title_full Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
title_fullStr Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
title_full_unstemmed Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
title_sort evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
publisher BMC
series Journal of Ovarian Research
issn 1757-2215
publishDate 2019-09-01
description Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients who benefited from NACT were further evaluated. Methods We retrospectively analyzed 220 patients who underwent NACT followed by IDS or PDS from January 2002 to December 2016. Differences in clinicopathological features, chemoresistance and prognosis were analyzed. Results The incidence rate for optimal cytoreduction and chemoresistance in the NACT group was relatively higher than PDS group. No differences were observed in progression free survival or overall survival. Patients without macroscopic RD in NACT group (NACT-R0) had a similar prognosis compared to those in PDS group who had RD<1 cm, and a relatively better prognosis compared to the PDS group that had RD ≥ 1 cm. The survival curve showed that patients in NACT-R0 group that were chemosensitive seemed to have a better prognosis compared to patients in PDS group that had RD. Conclusion Patients without RD after PDS had the best prognosis, whereas patients with RD after NACT followed by IDS had the worst. However, even if patients achieved no RD, their prognosis varied depending on chemosensitivity. Survival was better in patients who were chemosensitive compared to thosewho underwent PDS but had RD. Hence evaluating the chemosensitivity and feasibility of complete cytoreduction in advance is crucial.
topic Advanced ovarian epithelial Cancer
Neoadjuvant chemotherapy
Primary Debulking surgery
Chemoresistance
Prognosis
url http://link.springer.com/article/10.1186/s13048-019-0562-9
work_keys_str_mv AT yangao evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT yuanli evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT chunyuzhang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT jinsonghan evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT huamaoliang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT kunzhang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
AT hongyanguo evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy
_version_ 1724743127959339008